B7Y Stock Overview
Byotrol plc develops and commercialize antimicrobial technologies and products in the United Kingdom, North America, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Byotrol plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.0005 |
52 Week High | UK£0.019 |
52 Week Low | UK£0.0005 |
Beta | -0.40 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -93.33% |
3 Year Change | -99.17% |
5 Year Change | -97.50% |
Change since IPO | -98.39% |
Recent News & Updates
Recent updates
Shareholder Returns
B7Y | DE Chemicals | DE Market | |
---|---|---|---|
7D | 0% | 3.4% | 0.07% |
1Y | -93.3% | 5.0% | 4.9% |
Return vs Industry: B7Y underperformed the German Chemicals industry which returned 5% over the past year.
Return vs Market: B7Y underperformed the German Market which returned 4.9% over the past year.
Price Volatility
B7Y volatility | |
---|---|
B7Y Average Weekly Movement | 374.3% |
Chemicals Industry Average Movement | 4.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: B7Y's share price has been volatile over the past 3 months.
Volatility Over Time: B7Y's weekly volatility has increased from 243% to 374% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 36 | David Traynor | https://byotrolplc.com |
Byotrol plc develops and commercialize antimicrobial technologies and products in the United Kingdom, North America, and internationally. The company operates through Professional and Consumer segments. Its product portfolio includes Actizone, a antimicrobial technology which improves cleaning performance and long-lasting protection against bacteria; and Byotrol, a long-lasting antimicrobial protection for various applications including bathroom cleaners to multi-surface wipes.
Byotrol plc Fundamentals Summary
B7Y fundamental statistics | |
---|---|
Market cap | €2.12m |
Earnings (TTM) | -€2.16m |
Revenue (TTM) | €5.11m |
0.4x
P/S Ratio-1.0x
P/E RatioIs B7Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
B7Y income statement (TTM) | |
---|---|
Revenue | UK£4.38m |
Cost of Revenue | UK£2.52m |
Gross Profit | UK£1.86m |
Other Expenses | UK£3.72m |
Earnings | -UK£1.85m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0041 |
Gross Margin | 42.51% |
Net Profit Margin | -42.33% |
Debt/Equity Ratio | 19.7% |
How did B7Y perform over the long term?
See historical performance and comparison